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Pralidoxime for organophosphate poisoning
From their randomised trial, Kirti Pawar and colleagues 
report in today’s Lancet on two pralidoxime-dosing 
schemes in 200 patients who had moderately severe 
self-poisoning with organophosphorus insecticide.1 After 
a 2-g loading dose over 30 min, half received a high-dose 
regimen of 1 g/h pralidoxime iodide for 48 h. The other 
half received a lower dose: 1 g/h every 4 h.
After 48 h, the lower dose was continued in both groups 
until the patients could be weaned from the ventilator. 
The ﬁ gure shows the expected plasma concentrations of 
pralidoxime with each regimen.2 Patients who received 
the high-dose regimen had lower mortality (1% vs 8%) 
and less intubation and ventilator support, developed less 
muscle weakness, and required less atropine during the 
ﬁ rst day, and fewer developed pneumonia.
Pawar and colleagues’ study is the ﬁ rst known ran-
domised trial that includes large doses of pralidoxime, and 
suggests that higher doses would be superior to the lower 
dose (less than 6 g a day) intermittent bolus that is most 
commonly used in Asia. This region is important because it 
is where most of the pesticide poisoning in the world takes 
place and such poisoning accounts for about two-thirds 
of suicide deaths in the region. These results imply that 
maintaining higher plasma concentrations of pralidoxime 
allows the inhibited acetylcholinesterase to be reactivated 
faster, and provides clinical evidence to support laboratory 
studies2 showing the oft-cited optimum concentration of 
4 mg/L (15 µmol/L) is wildly incorrect.
Pawar and colleagues used pralidoxime iodide. Although 
the continuous high-dose infusion was well tolerated, an 
iodine load of about 11·5 g a day is not without risk—the 
recommended daily intake is just 0·1 mg. Therefore use of 
pralidoxime chloride or pralidoxime methanesulfonate is 
preferable, but the dose should account for the diﬀ erent 
molecular weights of the salts. For example, pralidoxime 
chloride is 1·53-times more potent than iodide salt. 
The high-dose regimen of iodide salt is equivalent to 
650 mg/h of the chloride salt, similar to the 8 mg/kg per h 
dose recommended by WHO guidelines.3
Pawar and colleagues’ study also challenges an-
other accepted assumption that dimethylated acetyl-
cholinesterase responds poorly to oximes because such 
drugs do not prevent the dimethyl ester from rapidly 
ageing (ageing refers to a further chemical reaction 
of the inhibited enzyme, which completely prevents 
subsequent reactivation). Two-thirds of the high-dose 
group had ingested dimethoate, which is more lethal 
and less responsive to oxime treatment,4 and yet their 
mortality was low at 1%. But this ﬁ nding might also be 
attributable to four favourable conditions in Pawar’s 
study that might not apply elsewhere. First, the time to 
admission was short (median 2 h) and pralidoxime was 
given soon after admission. Therefore the early high 
concentration of pralidoxime could then keep a high 
proportion of acetylcholinesterase active and theoretically 
prevent even the dimethyl ester ageing. Second, severely 
poisoned patients who were not successfully resuscitated 
in the emergency room were excluded. Third, there was no 
forced emesis, a procedure that probably results in more 
harm (from aspiration) than beneﬁ t.5 Fourth, Pawar’s 
hospital is well resourced compared with other hospitals 
in developing countries.
Nevertheless, Pawar and colleagues’ study has some 
major shortcomings that reduce conﬁ dence in the results. 
See Articles page 2136
Figure: Calculated pralidoxime plasma concentration, two-dose regimen
Calculated for 50-kg person. High dose=2-g bolus over 30 min, then continuous 
infusion of 1 g/h for 48 h, then 1 g/h every 4 h. Low dose=2-g bolus over 
30 min, then 1 g/h every 4 h.
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There were no data to conﬁ rm or explain a causal link 
between the treatment and the outcomes. The response 
of acetylcholinesterase and neuromuscular function were 
not measured, nor was the eﬀ ect of treatment on the 
pesticide concentration. Crucially, the speciﬁ c pesticide 
ingested was not even conﬁ rmed. There were also aspects 
of the trial design that might have inadvertently led to 
bias.6 For example, the trial was underpowered, there was 
no blinding, there was a small ﬁ xed-block size that could 
have undermined allocation concealment,7 and there 
was no reproducible algorithm for atropine dosing or 
pralidoxime cessation.
These problems might relate to the limited support 
for clinical research in Asia, especially for independent 
clinical investigators outside the few centres of excellence. 
Most future studies on pesticide poisoning will be in such 
settings in developing countries.8 Some thought should 
be given as to how best to support more activity, because 
there is no coordinated international eﬀ ort to address this 
problem at the moment, although there are lots of people, 
organisations, and governments who might be regarded 
as stakeholders. In a unique procedure supported by The 
Lancet, the reporting of this study was assisted by two 
reviewers, who reviewed most of the original data to assist 
the preparation of a revised manuscript, one of whom 
travelled on site to discuss critical issues with the authors. 
How much better would it have been to have this kind of 
advice before the trial starts?
Pralidoxime is expensive, and high doses might be 
unaﬀ ordable in many places. An aﬀ ordable pralidoxime 
preparation should be part of a public-health response 
to the considerable problem of pesticide poisoning in 
developing countries.8,9 We believe the drug will save lives, 
particularly in places where high-tech equipment is not 
available and many die simply because a respirator cannot 
be provided for every patient who needs one.10,11 However, 
this public-health problem would also be helped by better 
research support for investigators such as Pawar and 
colleagues, who should be highly commended for their 
endeavours.
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DDT: a polluted debate in malaria control
A recent press statement from WHO about dichloro-
diphenyltrichloroethane (DDT) and indoor residual spray-
ing for malaria control1 caused a considerable stir, despite 
the fact that, in terms of policy, it merely re-iterated 
WHO’s endorsement of DDT as a useful insecticide for 
malaria control, albeit in a highly promotional way. 
In this recurring debate, arguments for and against 
DDT, as before, have been heated and mainly based on 
considerations far removed from the realities of malaria 
control.
One group that criticised the WHO statement has 
inferred that my resignation from WHO’s Global Malaria 
Programme in September, 2006, was related to my 
opposition to its promotion of DDT.2 This assumption 
is erroneous. For many years, WHO’s malaria-control 
professionals have fought hard against pressure from 
various sides to ensure access in malaria-endemic 
countries to DDT.3 Hopefully, the statement now issued 
by the Global Malaria Programme1 will put an end to this 
debate, so that all countries that need DDT for malaria 
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